Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy

BACKGROUND: Currently, there are no recognized or validated biomarkers to identify hepatocellular carcinoma patients (HCC) likely to benefit from anti–PD‐1 therapy. We evaluated the relationship between neutrophil‐lymphocyte ratio (NLR) and platelet‐lymphocyte ratio (PLR) and survival outcomes, pret...

Descripción completa

Detalles Bibliográficos
Autores principales: Dharmapuri, Sirish, Özbek, Umut, Lin, Jung‐Yi, Sung, Max, Schwartz, Myron, Branch, Andrea D., Ang, Celina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367631/
https://www.ncbi.nlm.nih.gov/pubmed/32419290
http://dx.doi.org/10.1002/cam4.3135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367631/
https://www.ncbi.nlm.nih.gov/pubmed/32419290
http://dx.doi.org/10.1002/cam4.3135

Ejemplares similares